Commercial Launch Of Liquid Biopsy Test For Lung Cancer (#GotBitcoin?)
Biocept’s Stock Soars On Heavy Volume After Commercial Launch Of Liquid Biopsy Test For Lung Cancer. Commercial Launch Of Liquid Biopsy Test For Lung Cancer (#GotBitcoin?)
Shares of Biocept Inc. BIOC, +85.37% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer.
Trading volume spiked to 60.9 million shares, compared with the full-day average of about 733,000 shares.
“The Target Selector™ NGS Lung Panel will be marketed to physicians and researchers, and can be used to detect and monitor actionable biomarkers associated with lung cancer,” the company said in a statement. The stock was still down 73% over the past 12 months, while the S&P 500 SPX, -0.88% has gained 4.5%.